Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

2020468 citationsJournal Articlegreen Open Access

Authors

Reduced inequalities

Published in: The Lancet Neurology

Volume 19, Issue 5, pp. 402-412

Field-Weighted Citation Impact: 39.60